How much time this disease allows
71anti-CD38-refractory del(17p) myelomarenal impairment, AFfar from the bispecific center
Move fast, or narrow the field first?
66%
Comorbidity and reconfirmation
34%
Urgency of the disease
What matters now
Retrospective analyses now identify cure in multiple myeloma after CAR T-cell therapy. One-third of evaluated patients remained disease-free.
71anti-CD38-refractory del(17p) myelomarenal impairment, AFfar from the bispecific center
Move fast, or narrow the field first?
66%
Comorbidity and reconfirmation
34%
Urgency of the disease
61newly diagnosed myeloma, transplant-eligiblet(4;14), ECOG 1, reduced creatinine clearance
Adjust the dose, or change the regimen?
35%
Dose adjustment
65%
A different regimen
58standard-risk myeloma, MRD-negative on maintenancefeels well, no longitudinal plan written
Depth and risk, or how she feels?
22%
Response depth and risk
78%
Regimen, imaging and symptoms
78transplant-ineligible myelomaECOG 2, heart failure, diabetes, polypharmacy, limited support
Measure her fitness, or manage around it?
28%
A fitness measurement
72%
Comorbidity, support and stage
67fitfirst biochemical relapse after quadruplet, transplant and maintenanceneuropathy
The exposure, or the disease behavior?
84%
Biology, duration and timing
16%
The recent exposure
What matters now
Retrospective analyses now identify cure in multiple myeloma after CAR T-cell therapy. One-third of evaluated patients remained disease-free.
5 Real World Scenarios
71anti-CD38-refractory del(17p) myelomarenal impairment, AFfar from the bispecific center
Move fast, or narrow the field first?
Where does the evidence land?
66%
Comorbidity and reconfirmation
34%
Urgency of the disease
61newly diagnosed myeloma, transplant-eligiblet(4;14), ECOG 1, reduced creatinine clearance
Adjust the dose, or change the regimen?
Where does the evidence land?
35%
Dose adjustment
65%
A different regimen
58standard-risk myeloma, MRD-negative on maintenancefeels well, no longitudinal plan written
Depth and risk, or how she feels?
Where does the evidence land?
22%
Response depth and risk
78%
Regimen, imaging and symptoms
78transplant-ineligible myelomaECOG 2, heart failure, diabetes, polypharmacy, limited support
Measure her fitness, or manage around it?
Where does the evidence land?
28%
A fitness measurement
72%
Comorbidity, support and stage
67fitfirst biochemical relapse after quadruplet, transplant and maintenanceneuropathy
The exposure, or the disease behavior?
Where does the evidence land?
84%
Biology, duration and timing
16%
The recent exposure